GeneDx (NASDAQ:WGS) Shares Down 5.1% on Insider Selling

Key Points

• GeneDx Holdings Corp. (NASDAQ:WGS) shares fell by 5.1% following significant insider selling, with a director selling 500,000 shares for approximately $60.45 million.
• Wall Street analysts have mixed ratings on GeneDx, with price targets ranging from $80.00 to $135.00, and a consensus rating of "Moderate Buy".
• The company's latest earnings report showed a profit of $0.50 EPS, surpassing analysts' expectations, and it has set a guidance of 0.97 EPS for the current year.

GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) shares traded down 5.1% on Monday following insider selling activity. The stock traded as low as $122.42 and last traded at $122.10. 325,200 shares traded hands during mid-day trading, a decline of 69% from the average session volume of 1,062,925 shares. The stock had previously closed at $128.66.

Specifically, Director Casdin Capital, Llc sold 500,000 shares of the firm's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $120.90, for a total value of $60,450,000.00. Following the completion of the transaction, the director directly owned 3,007,164 shares of the company's stock, valued at approximately $363,566,127.60. This trade represents a 14.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. TD Securities decreased their target price on GeneDx from $135.00 to $110.00 and set a "buy" rating for the company in a research report on Thursday, May 1st. Jefferies Financial Group raised shares of GeneDx from a "hold" rating to a "buy" rating and set a $80.00 price objective for the company in a research note on Friday, May 9th. Wells Fargo & Company upped their price objective on shares of GeneDx from $78.00 to $95.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 30th. Wall Street Zen raised shares of GeneDx from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Finally, Guggenheim reaffirmed a "buy" rating and issued a $115.00 price objective (up from $88.00) on shares of GeneDx in a research note on Monday, June 30th. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat, GeneDx has a consensus rating of "Moderate Buy" and an average price target of $101.63.

GeneDx Stock Down 4.5%

The company has a current ratio of 2.87, a quick ratio of 2.70 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $3.53 billion, a PE ratio of 2,454.70 and a beta of 2.02. The business has a fifty day moving average of $93.85 and a 200 day moving average of $87.67.

GeneDx (NASDAQ:WGS - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $0.50 earnings per share for the quarter, beating analysts' consensus estimates of $0.10 by $0.40. The firm had revenue of $102.69 million for the quarter, compared to the consensus estimate of $86.00 million. GeneDx had a return on equity of 16.51% and a net margin of 0.39%. GeneDx has set its FY 2025 guidance at EPS. Equities research analysts anticipate that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Institutional Trading of GeneDx

Hedge funds have recently made changes to their positions in the stock. Wells Fargo & Company MN grew its holdings in shares of GeneDx by 42.0% in the 4th quarter. Wells Fargo & Company MN now owns 8,382 shares of the company's stock worth $644,000 after acquiring an additional 2,480 shares during the last quarter. Envestnet Asset Management Inc. acquired a new stake in GeneDx in the 4th quarter valued at about $380,000. Legal & General Group Plc grew its stake in shares of GeneDx by 31.1% during the fourth quarter. Legal & General Group Plc now owns 11,123 shares of the company's stock valued at $855,000 after purchasing an additional 2,638 shares during the last quarter. Dimensional Fund Advisors LP bought a new stake in shares of GeneDx during the fourth quarter valued at approximately $1,080,000. Finally, MetLife Investment Management LLC grew its stake in shares of GeneDx by 6.2% during the fourth quarter. MetLife Investment Management LLC now owns 7,750 shares of the company's stock valued at $596,000 after purchasing an additional 453 shares during the last quarter. Institutional investors own 61.72% of the company's stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.